Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.03 (-2.08%)
Close on Nov 17, 2026Market cap $6.31MP/E –Yield –
Enveric Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Enveric Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$8.73M. For fiscal 2025 it was -$8.77M. The highest annual figure on record is $32.81K in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.77M | – |
| FY2024 | Dec 31, 2024 | -$9.63M | – |
| FY2023 | Dec 31, 2023 | -$16.45M | – |
| FY2022 | Dec 31, 2022 | -$27.42M | – |
| FY2021 | Dec 31, 2021 | -$64.62M | – |
| FY2020 | Dec 31, 2020 | -$5.62M | – |
| FY2019 | Dec 31, 2019 | -$2.30M | – |
| FY2018 | Dec 31, 2018 | -$7.15M | – |
| FY2017 | Dec 31, 2017 | -$10.90M | – |
| FY2016 | Dec 31, 2016 | -$5.38M | – |
| FY2015 | Dec 31, 2015 | -$793.98K | -2519.9% |
| FY2014 | Dec 31, 2014 | $32.81K | +20.6% |
| FY2013 | Dec 31, 2013 | $27.21K | – |
| FY2012 | Dec 31, 2012 | -$22.69K | – |
| FY2011 | Dec 31, 2011 | -$31.40K | – |
| FY2010 | Dec 31, 2010 | -$35.88K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.08M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.45M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.66M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.71M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$50.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.36M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.52M | -272.4% |
| Q3 FY2020 | Sep 30, 2020 | -$489.83K | – |
| Q2 FY2020 | Jun 30, 2020 | -$767.51K | – |
| Q1 FY2020 | Mar 31, 2020 | -$836.70K | – |
| Q4 FY2019 | Dec 31, 2019 | $2.04M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.57M | -125.7% |
| Q2 FY2019 | Jun 30, 2019 | -$1.48M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.30M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.80M | – |
| Q3 FY2018 | Sep 30, 2018 | $6.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.37M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.21M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.95M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$630.55K | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.17M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.29M | – |
See a number that looks wrong?